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Abstract  
Human Growth Hormone (hGH) is a monomeric 22 kilo Dalton (kDa), 191 amino acid protein with an isoelectric point (pI) close 
to pH 5, produced in the anterior pituitary gland. High level production of somatropin (recombinant hGH) is done in Escherichia 
coli (E. coli) to meet the demand and to avoid possible Creutzfeldt-Jacob disease (CJD). 
The present study was initiated on the basis of results from post-marketing control of all somatropin preparations on the 
Norwegian market. The samples consisted of preparations presented as somatropin in solution, and some freeze-dried 
preparations were also included for comparison. 
The present study showed a significant degree of degradation of somatropin in solution. Deamidation increased over time for 
preparations in solution, as well as for freeze-dried preparations after dissolution. Preparations in solution showed high content of 
deamidated and cleaved forms. Freeze-dried preparations after dissolution and storage showed high content of deamidated forms, 
but low content of cleaved forms. Also, in one preparation, an unknown peak was detected in the electropherogram from 
capillary zone electrophoresis (CZE), eluting after the principal peak, in front of the Gln-18 somatropin peak. 
a
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1. Introduction 
Mammalian growth hormones (GH) are heterogeneous proteins consisting of several isoforms and variants. The 
sources of the variety in forms reside at the level of the genome, mRNA splicing, post-translational modification and 
metabolism [1]. The 22 kDa form of human GH (hGH), first isolated in 1956 [2] and characterized in 1971 [3], is 
the main and most abundant form of GH in the pituitary gland. Post-translational modifications of 22 kDa GH 
include an amino-acylated form and two deamidated forms [4]. The deamidation occurs at amino acid positions 137 
and 152. 
There are minor differences in somatogenic and metabolic bioactivity among the GH variants, depending on 
species and assay systems used. The deamidated and acylated forms have similar growth-promoting and 
diabetogenic activity in rodents [1], and also in an in vitro cell proliferation assay. However, there is limited 
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information available concerning the distribution of the biological activities of GH among the different variants. 
This is mainly due to the unavailability of these variants in pure form. 
The different recombinant somatropin (rhGH) preparations on the market are mostly produced in E. coli, 
however, some of the products are also made in mammalian cell lines. This may confer structural modifications to 
somatropin preparations other than the ones resulting from production in bacteria. 
The prototype of what we today know as a capillary electrophoresis system (CE) was made in 1967 [5]. 
Electrophoresis in this system was based on a 1-3 mm rotating tube. The rotation was necessary to prevent 
sedimentation. In 1988 Browniee and Bio-Rad Laboratories introduced commercially available capillary 
electrophoresis equipment for capillaries <100 µm internal diameter (ID). Five years later there were ten producers 
of CE equipment world wide. 
The following references have demonstrated a great application potential of capillary zone electrophoresis (CZE) 
for analysis of proteins and polypeptides in general, and for rhGH in particular [6-10]. 
CE was established as an analytical method in the European Pharmacopoeia (Ph. Eur.) in 2001 [11], and 
introduced in the monograph erythropoietin (EPO) concentrated solution in 2002 [12]. In 2006, the test for isoform 
distribution by isoelectric focusing (IEF) in the somatropin monographs was replaced by CZE [13].  
Ph. Eur. describes the reference electropherogram of somatropin  chemical reference substance (CRS) batch 2 
made in E. coli (fig. 1) with two impurity peaks (I1 and I2), eluting prior to the principal peak, and at least two peaks 
(I3 and I4) eluting after the principal peak. I2 corresponds to a cleaved form of somatropin, I3 corresponds to Gln-18 
somatropin and peak I4 corresponds to the deamidated forms, eluting as a doublet. The British Pharmacopoeia (BP) 
[14] describes three peaks eluting after the principal peak; I3, I4 and I5. Ph. Eur. and BP have defined the following 
 
Fig. 1 Reference electropherogram of charged variants distribution of somatropin CRS batch 2 (Ph. Eur.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 I = impurity. 
I1, I2 (cleaved form), I3 (Gln-18 somatropin), I4 (deamidated forms). 
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limits for these components: Maximum 6.5 % deamidated forms; for any other impurity, maximum  2.0 % is 
allowed of each, and maximum 11.5 % of total impurities (ITotal). 
The present study was initiated on the basis of results from post-marketing control at the Norwegian Medicines 
Agency (NoMA) of all somatropin preparations available on the Norwegian market, sampled by the end of 2007. 
The samples consisted of preparations presented as somatropin in solution as well as freeze-dried preparations 
intended for reconstitution immediately before use, the latter corresponding to the Ph. Eur. monograph somatropin 
for injection [13]. 
The analytical results complied with the specifications of the Ph. Eur., except for the content of deamidated 
forms. At about one year before expiry date, the batches with somatropin in solution had an estimated content of 
desamido somatropin just above the limit of 6.5 % of the Ph. Eur. However, these results could not be considered as 
out of specification (OOS) results, because the Ph. Eur. monograph is not representative for the concerned 
pharmaceutical formulations, and the manufacturers’ product specifications did not include the test for charged 
variants by CZE, nor describes any limit for the content of deamidated forms in their somatropin products. 
Obviously, there is a need for a pharmacopoeia monograph on injectable somatropin marketed as a solution. The 
limits for the content of degradation products and the shelf life of the preparation will probably be a matter of 
consideration for the Ph. Eur. Commission in their work with revision of the somatropin monograph. 
In the present study, to investigate the suitability of CZE to study degradation during storage, two brands of 
somatropin injection in solution available on the Norwegian market were tested. For comparative investigations also 
samples of the freeze-dried preparations of somatropin were tested at various time points after dissolution. 
 
2. Experimental 
2.1. Chemicals 
Somatropin CRS batch 2 was obtained from the European Directorate for the Quality of Medicines & HealthCare 
(EDQM), Strasbourg, France. The somatropin reference was kept at -20 oC until use. 
The somatropin preparations were obtained from a medicinal products wholesaler, Norsk Medisinaldepot, Oslo, 
Norway. Norditropin SimpleXx batch TR40418 was obtained from Novo Nordisk AS, Bagsværd, Denmark. The 
preparations were kept at 4 oC. 
(NH4)2HPO4, NaOH and ortho-Phosphoric acid 85 % were obtained from Merck, Darmstadt, Germany. 
Fluorinated liquid (FC-77) was obtained from 3M, Chemical Group, Haven, Belgium. Buffers and solutions were 
degassed before use at 3-6 bar and filtered through a 0.45 µm filter (Millex-HA, Millipore, Bedford, Massachusetts, 
USA). Milli-Q-H2O (MQ-H2O) was prepared with Elix 10, Milli-Q Synthesis A10 from Millipore Corporation, 
Bedford, Massachusetts, USA. 
2.2. Handling of samples 
Somatropin CRS batch 2, 1.69 mg of somatropin monomer, was dissolved in MQ-H2O to a final concentration of 
1.0 mg/ml. 
Test samples in solution, Norditropin SimpleXx and NutropinAq, were diluted with MQ-H2O to a final 
concentration of 1.0 mg/ml. 
Freeze-dried samples were dissolved in their respective solvents and diluted with MQ-H2O to a final 
concentration of 1.0 mg/ml. 
All test solutions were kept at 4 oC. 
2.3. Capillary zone electrophoresis (CZE) of somatropin samples 
The BioFocus 3000 Capillary Electrophoresis System with Spectra Software version 3.00, Integration Software 
version 3.01, and BioFocus Capillary Cartridge from Bio-Rad Laboratories, California, USA, were used for the 
somatropin analysis. Uncoated fused silica capillaries from Polymicro Technologies, Arizona, USA, 74.8 cm x 50 
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µm ID (70.1 cm to the detection window) were used for the separation.  The CZE experiments were performed in 
ammonium phosphate buffer 150 mM (19.81 g of (NH4)2HPO4 was dissolved in 950 ml MQ-H2O and titrated to pH 
6.0 with ortho-Phosphoric acid 85 % and MQ-H2O was added to 1000.0 ml). The individual experiments were 
performed at constant voltage (14 kV), giving a maximum current of 110 µA in the capillary. 
All samples were applied hydrodynamically by pressure (2 p.s.i. x 1 s; 1 p.s.i. = 6894.76 Pa) and analysed with 
polarity from the positive to the negative electrode. The cartridge and the carousel were thermostated at 30 oC and 5 
oC, respectively, by the Peltier thermoelectric cooling system with fluorinated liquid. 
The washing procedure for the system between each run was as follows; initially, 100 mM sodium hydroxide for 
120 s, then MQ-H2O for 60 s, then electrophoresis buffer for 300 s, and finally MQ-H2O for 0 s. Absorbance was 
monitored at 200 nm. 
3. Results and discussion 
Tables 1 and 2 give an overview of the somatropin preparations on the Norwegian market. Four preparations are 
freeze-dried formulations and two are presented as somatropin in solution. All, except one, of the preparations are 
prepared by recombinant DNA technology using  E. coli as the host organism. For one product (Saizen) transformed 
mammalian cells are utilized. Tables 2.A and B show the composition of each preparation with declaration of 
ingredients and solvents. Detergents are included in the composition of the somatropin preparations in solution, 
probably to stabilize the product. 
The distribution of charged variants in the somatropin preparations, as well as in somatropin CRS batch 2 were 
analysed at various time points after storage at 4 oC. 
 Fig. 2.A and B show the distribution profiles for somatropin CRS batch 2 solution immediately after preparation 
and after 285 days, respectively. Particularly, the content of impurity I4, corresponding to the deamidated forms, 
showed a prominent increase during storage at 4 ºC. This is also demonstrated in fig. 3 (the x-axis is not linear). 
Tables 3.A and B show the content of charged forms for all preparations before and after storage of the test 
solutions. For all batches, except one, the level of deamidated forms (I4) had raised above or were close to, the limit 
of 6.5 % defined in the somatropin for injection monograph, indicating a significant degradation. However, this limit 
is not formally applicable to the preparations of somatropin in solution (Norditropin SimpleXx and NutropinAq), 
and regarding the freeze-dried somatropin preparations these are not intended for storage after reconstitution. 
 
Table 1. Somatropin preparations tested. 
 
Product Package Expiry Formulation Production method 
Norditropin SimpleXx: 10 mg/1.5 ml 09/2008 solution rDNA, E.coli 
5 mg/1.5 ml 11/2008 solution rDNA, E.coli 
5 mg/1.5 ml 12/2008 solution rDNA, E.coli 
5 mg/1.5 ml 05/2009 solution rDNA, E.coli 
NutropinAq: 10 mg/2 ml 04/2009 solution rDNA, E.coli 
     
Genotropin: 0.4 mg 09/2008 freeze-dried rDNA, E.coli 
5 mg 09/2009 freeze-dried rDNA, E.coli 
Humatrope: 12 mg 01/2009 freeze-dried rDNA, E.coli 
Saizen: 1.33 mg 05/2008 freeze-dried rDNA, transformed 
mammalian cells 8 mg 10/2009 freeze-dried 
Zomacton: 4 mg 11/2008 freeze-dried rDNA, E.coli 
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Table 2.A Declared content of somatropin preparations on the Norwegian market: Solutions for injection. 
 
Product rhGH 
mg 
NaCl 
mg 
Phenol 
mg 
Polysorbate 
20 
NaCitrate 
mg 
Citric acid 
mg 
Histidine 
mg 
Poloxamer 
188 
Mannitol 
mg 
Aq. 
ml 
Norditropin 
SimpleXx…: 5-15 - x - - - x x x 1.5 
NutropinAq: 10 x x x x x - - - 2 
 
 
 
Table 2.B Declared content of somatropin preparations on the Norwegian market: Freeze-dried preparations. 
 
 Freeze-dried substance Solvent 
Product rhGH 
mg 
Glycine 
mg 
Mannitol 
mg 
Saccharose 
mg 
NaH2PO4 
mg 
Na2HPO4 
mg 
NaCl 
mg 
NaOH 
mg 
NaCl 
mg 
Mannitol 
mg 
Benzyl- 
alcohol 
mg 
m-Cresol 
mg 
Glycerol 
mg 
Aq. 
ml 
Genotropin: 0.2-2 0.21 1.04 - 0.045 0.025 - - - 11.5 - - - 0.25 
5 2 1.8 - 0.28 0.27 - - - 39 - 3 - 1 
12 2 12.2 - 0.41 0.4 - - - 27.8 - 3 - 1 
               
Humatrope: 6 6 18 - - 1.36* - - - - - 9.45 53.55 3.15 
12 12 36 - - 2.72* - - - - - 9.45 9.14 3.15 
24 24 72 - - 5.43* - - - - - 9.45 9.14 3.15 
               
Saizen: 1.33 - 20 - x** x*** x - 9/ml - - - - x 
3.33 - 5 - x** x*** - - 9/ml - 9/ml - - 5 
8 - - 54.7 x** x*** - x - - - 3/ml - 1.37 
               
Zomacton: 4 - 25.9 - - - - - 31.5 - 31.5 - - 3.5 
 
 
* = Na2HPO4 7H2O, ** =  NaH2PO4 H2O,  *** = Na2HPO4 2H2O. 
x = Amount/volume not given. 
Poloxamer = Poloxamer 188 = Exocorpol, Pluronic F68. 
Polysorbat 20 = Tween 20 
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 Fig. 2 Electropherogram of somatropin CRS batch 2, 1.0 mg/ml, freshly prepared  (A) and after 285 days (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I = impurity. 
I1, I2 (cleaved form), I3 (Gln-18 somatropin), I4 (deamidated forms), I5(deamidated form). 
 
A B 
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Fig. 3 Degradation of somatropin CRS batch 2, 1.0 mg/ml; monitored during storage at 4 oC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
I = impurity. 
 DD (%) = degradation degree in per cent. 
 
The degradation of each preparation of somatropin in solution is shown in fig. 4.A-E. A steady increase in the 
level of degraded forms of somatropin (desamido forms) is demonstrated over time for all products. For comparison, 
degradation of each of the reconstituted freeze-dried preparations is shown in fig. 5.A-F. As might be expected, a 
more prominent increase in degradation is demonstrated when these preparations are stored in solution at 4 oC. 
The values estimated for impurities, including the deamidated forms of somatropin may be useful in 
considerations for setting limits in a pharmacopoeia monograph on somatropin injection. The following estimates 
for the content of deamidated forms (I4) after storage were obtained for the batches of somatropin preparations in 
solution marketed in Norway (number of months until expiry date indicated in parenthesis): 9.6 % (0), 10.0 % (2), 
3.5 % (3), 6.7 % (8) and 6.2 % (7), see table 3.B. Regarding degradation it has been reported that also the 
deamidated forms of somatropin have growth promoting activity [1, 15, 16]. Regarding the relatively high content 
of degraded forms demonstrated in the somatropin preparations, assurance must be established that their activity is 
qualitatively and quantitatively similar to the activity of the principal form of somatropin, and that no additional 
unwanted effects are developed. On the other hand it is not acceptable that the active substance of a medicinal 
product shifts from a pure substance to an inhomogeneous mixture of related chemical entities during its shelf life.  
Additional degradation products and also changes in their relative content during storage, have been considered 
during these stability studies (tables 3.A and B). However, due to batch variations in Norditropin SimpleXx is a 
complicating factor, and further assessment is needed. 
 
I1 
ITotal 
I2 
I3 
I5 
I4 
D
D
 
(%
) 
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 Table 3.A  Content of charged somatropin variants of initial test solutions (%). 
 
Product Expiry Date I1 I2 I3 I4 I5 ITotal 
Norditropin  
SimpleXx: 
09/2008 21.11.07 1.67 0.57 0.61 6.55 0.00 9.40 
11/2008 05.12.07 1.29 0.22 0.52 6.91 0.00 8.94 
12/2008 28.02.08 1.20 0.35 0.16 1.24 0.07 3.02 
05/2009 03.03.08 1.23 0.24 0.30 4.27 0.00 6.04 
NutropinAq: 04/2009 19.12.07 2.92 0.00 0.39 3.06 0.00 6.37 
         
Genotropin: 09/2008 03.12.07 0.33 0.00 0.06 0.29 0.00 0.68 
09/2009 04.12.07 0.28 0.00 0.08 0.22 0.00 0.58 
Humatrope : 01/2009 26.11.07 0.30 0.00 0.45 1.80 0.00 2.55 
Saizen: 05/2008 27.11.07 0.08 0.04 0.46 1.10 0.51 2.19 
10/2009 30.11.07 0.25 0.08 0.17 1.00 0.58 2.08 
Zomacton: 11/2008 24.12.07 0.35 0.48 0.44 2.02 0.00 3.29 
 
I1, I2 (cleaved form), I3 (Gln-18 somatropin), I4 (deamidated forms), I5 (deamidated form). 
 
Table 3.B  Content of charged somatropin variants after storage at 4 oC (%). 
 
Product Expiry No. of days I1 I2 I3 I4 I5 ITotal 
Norditropin  
SimpleXx: 
09/2008 275 0.79 0.34 0.41 9.63 0.03 11.20 
11/2008 273 0.80 0.14 0.40 9.95 0.00 11.29 
12/2008 187 1.12 0.27 0.21 3.50 0.04 5.14 
05/2009 188 1.00 0.26 0.32 6.68 0.00 8.26 
NutropinAq: 04/2009 260 1.39 0.06 0.54 6.22 0.00 8.21 
         
Genotropin: 09/2008 285 0.10 0.16 0.43 9.26 0.00 9.95 
09/2009 285 0.18 0.00 0.39 8.38 0.00 8.95 
Humatrope: 01/2009 284 0.00 0.00 0.90 15.46 0.00 16.36 
Saizen: 05/2008 283 0.00 0.93 2.04 19.98 0.00 22.95 
10/2009 281 0.00 0.14 1.85 17.26 0.04 19.29 
Zomacton: 11/2008 257 0.00 0.64 0.76 11.55 0.00 12.95 
 
 
Fig. 6 shows the eletropherograms for the initial test solutions of two strengths of a somatropin preparation in 
solution (Norditropin SimpleXx), and two strengths of one of a freeze-dried preparation (Saizen) before storage, 
demonstrating the distribution of the charged variants of somatropin. Concerning the latter preparation, an additional 
peak eluting just after the principal peak, in front of Gln-18 somatropin (I3), was observed. This component, not 
described in the pharmacopoeias, designated I?, may be due to the different production method for this somatropin 
preparation. 
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 Fig.4 Degradation of somatropin preparations in solution after dilution/preparation of test solution 1.0 mg/ml: 
(A) Norditropin SimpleXx 10mg/1.5ml batch TU60933 exp.09/2008, (B) Norditropin SimpleXx 5mg/1.5ml batch TU60855 exp.11/2008, (C) Norditropin 
SimpleXx 5mg/1.5ml batch TR40418 exp.13dec 2008, (D) Norditropin SimpleXx 5mg/1.5ml batch TU61386 exp.05/2009, (E) NutropinAq 10mg/2ml batch 
SOO5(N67268) exp.04/2009. 
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 Fig.5 Degradation of freeze-dried somatropin preparations after reconstitution and preparation of test solution 1.0 mg/ml: 
(A) Genotropin 0.4mg batch PO2483 exp.09/2008, (B) Genotropin 5mg batch PO1548 exp.09/2009, (C) Humatrope 12mg batch A324817 exp.01/2009, (D) 
Saizen 1.33mg batch YO3A8242 exp.05/2008, (E) Saizen 8mg batch YO5B4666 exp.10/2009, (F) Zomacton 4mg batch CA0760G exp.11/2008. 
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 Fig.6  Electropherogram of initial test solutions, 1.0 mg/ml.  
(A) Norditropin SimpleXx 10mg/1.5ml, exp.09/2008.  
(B) Norditropin SimpleXx 5mg/1.5ml, exp.12/2008.  
(C) Saizen 1.33 mg, exp. 05/2008  
(D) Saizen 8 mg, exp.11/2008. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I = impurity. 
I1, I2 (cleaved form), I? (unknown), I3 (Gln-18 somatropin), I4 (deamidated forms). 
 
The rhGH profile shown in fig. 6.A and B is produced in E. coli, however, somatropin in Saizen (fig. 6.C and D) 
is made in a mammalian cell line, and as a consequence, post-translational modifications other than the ones 
occurring in bacteria are likely to happen. For instance, mammalian cells are able to glycosylate recombinant 
proteins while proteins produced in E. coli do not contain sugar. 
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 The additional peak seen in fig. 6.C and D in the rhGH profile from mammalian cells compared to the profiles of 
somatropin produced in E. coli, might represent a glycosylated form [1, 17]. The existence of a glycosylated variant 
from the human pituitary gland has previously been shown, probably containing O-linked sugar [17], and 
glycosylated forms of both chicken and murine [18, 19] GH have been reported. 
4. Conclusion 
The results demonstrate the existence of many rhGH variants in the somatropin preparations on the market. Peaks 
corresponding to both deamidated, cleaved and also unknown variants are present in the profiles after CZE. In 
addition an increasing content of modified/degraded forms have been shown in the recombinant somatropin 
solutions after storage at 4 oC. 
A pharmacopoeia standard also for somatropin presented as an injection solution, including acceptance limits for 
the concerned impurities, is needed. 
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